UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2268-6
Program Prior Authorization/Medical Necessity
Medication Tarpeyo® (budesonide delayed-release capsules)
P&T Approval Date 2/2022, 4/2022, 7/2022, 7/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Tarpeyo (budesonide delayed-release capsule) is indicated to reduce the loss of kidney function
in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease
progression.
2. Coverage Criteriaa:
A. Authorization
1. Tarpeyo will be approved based on all of the following:
a. Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by renal
biopsy
-AND-
b. Patient is at risk for disease progression
-AND-
c. Used to reduce the loss of kidney function
-AND-
d. Estimated glomerular filtration rate (eGFR) ≥ 35 mL/min/1.73 m2
-AND-
e. One of the following:
1) Patient is on a stabilized dose and receiving concomitant therapy with one of the
following:
a) maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g.
captopril, enalapril)
b) maximally tolerated angiotensin II receptor blocker (ARB) (e.g. candesartan,
valsartan)
-OR-
© 2025 UnitedHealthcare Services Inc.
1
2) Patient has an allergy, contraindication, or intolerance to ACE inhibitors and
ARB
-AND-
f. History of failure, contraindication or intolerance to a 30-day trial of a glucocorticoid
(e.g., methylprednisolone, prednisone)
-AND-
g. Prescribed by or in consultation with a nephrologist
Authorization will be issued for 9 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic
class.
• Supply limits may be in place.
4. References:
1. Tarpeyo [package insert]. Stockholm, Sweden: Calliditas Therapeutics AB; June 2024
2. KDIGO 2021 Glomerular Diseases Guideline. October 2021; 100 (4S).
Program Prior Authorization/Medical Necessity – Tarpeyo
Change Control
Date Change
2/2022 New program
4/2022 Removed Immunologist prescriber requirement and updated urine
protein-to-creatinine ratio (UPCR) of ≥ 1.5 g/g to be an example along
with the International IgAN Prediction Tool.
7/2022 Added requirement of IgAN confirmed by renal biopsy and a 30-day
trial of a glucocorticoid.
7/2023 Annual review. No changes.
2/2024 Updated indication and removed example for disease progression.
Updated references.
2/2025 Annual review. Updated references.
© 2025 UnitedHealthcare Services Inc.
2